huLAG-3-NF-AT-Jurkat,
- Product Code: 250773
| Molecular Weight: | Molecular Formula: | ||
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -80℃ |
Product Description:
This compound is not a chemical in the traditional sense but refers to a genetically engineered cell line—specifically, a modified Jurkat T-cell line expressing human LAG-3 and an NF-AT (nuclear factor of activated T-cells) reporter system. It is primarily used in immunological research and drug development.
The main application lies in studying immune checkpoint pathways, particularly the LAG-3 (Lymphocyte-Activation Gene 3) receptor, which plays a critical role in downregulating T-cell activation. This cell line is used to screen and evaluate potential therapeutic agents such as blocking antibodies or small molecules targeting the LAG-3 pathway. Activation of LAG-3 in these cells leads to measurable NF-AT-driven reporter signals (e.g., luciferase or GFP), allowing quantitative assessment of T-cell inhibition or its reversal.
It is widely used in high-throughput screening for cancer immunotherapies, especially in developing combination therapies with other checkpoint inhibitors like PD-1 or CTLA-4. The system provides a reproducible and sensitive platform for assessing the functional activity of biologics and small molecules in modulating T-cell responses.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 5E6cells/EA | 10-20 days | ฿432,430.00 |
+
-
|
huLAG-3-NF-AT-Jurkat,
This compound is not a chemical in the traditional sense but refers to a genetically engineered cell line—specifically, a modified Jurkat T-cell line expressing human LAG-3 and an NF-AT (nuclear factor of activated T-cells) reporter system. It is primarily used in immunological research and drug development.
The main application lies in studying immune checkpoint pathways, particularly the LAG-3 (Lymphocyte-Activation Gene 3) receptor, which plays a critical role in downregulating T-cell activation. This cell line is used to screen and evaluate potential therapeutic agents such as blocking antibodies or small molecules targeting the LAG-3 pathway. Activation of LAG-3 in these cells leads to measurable NF-AT-driven reporter signals (e.g., luciferase or GFP), allowing quantitative assessment of T-cell inhibition or its reversal.
It is widely used in high-throughput screening for cancer immunotherapies, especially in developing combination therapies with other checkpoint inhibitors like PD-1 or CTLA-4. The system provides a reproducible and sensitive platform for assessing the functional activity of biologics and small molecules in modulating T-cell responses.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :